Can a targeted drug keep High-Risk breast cancer from returning?
NCT ID NCT01805271
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This phase III trial is testing whether adding the drug everolimus to standard hormone therapy can help prevent breast cancer from coming back in women with ER-positive, HER2-negative breast cancer who are at high risk of relapse. Participants have already completed at least one year of hormone therapy and remain disease-free. The study compares everolimus against a placebo, with the main goal of seeing if the combination improves disease-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- everolimus (Afinitor)
- What this could lead to
- If successful, this could offer a new way to lower the chance of breast cancer returning in women at high risk, potentially improving long-term survival.
- What could go wrong
- The trial is large but still experimental. Everolimus can cause side effects like mouth sores, infections, and metabolic changes, and it may not prove more effective than hormone therapy alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY NON-METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Leon Berard
Lyon, France
-
Gustave Roussy
Villejuif, France